Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

@article{Herman2014IbrutinibIB,
  title={Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.},
  author={Sarah E M Herman and Rashida Z. Mustafa and Jennifer Afosaa Gyamfi and Stefania Pittaluga and Stella L Chang and Betty Y. Chang and Mohammed Z.H. Farooqui and Adrian Wiestner},
  journal={Blood},
  year={2014},
  volume={123 21},
  pages={3286-95}
}
Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental factors for proliferation and survival. In particular, tissue-resident CLL cells show prominent activation of both B-cell receptor (BCR) and NF-κB pathways. We evaluated the in vivo effects of ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor on tumor cell activation and proliferation in the blood, lymph node, and bone marrow of patients with CLL. Applying validated pathway-specific gene signatures, we detected a rapid and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Similar Papers

Loading similar papers…